<DOC>
	<DOCNO>NCT00185185</DOCNO>
	<brief_summary>This study hypertensive patient atherosclerosis increase cardiovascular risk . The efficacy olmesartan medoxomil atherosclerosis measure .</brief_summary>
	<brief_title>Olmesartan Medoxomil Atherosclerosis</brief_title>
	<detailed_description />
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Olmesartan</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<mesh_term>Atenolol</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<criteria>Mean sit sBP dBP prior randomization 140180/90105 mmHg Increased cardiovascular risk , e.g . : ) document clinical sign peripheral atherosclerotic disease stage IIa low ; b ) diabetes mellitus type 2 ; c ) leave ventricular hypertrophy echo ; ) current smoking ; e ) old myocardial infarction , stroke TIA Intimamedia thickness common carotid artery great equal 0.8 less equal 1.6 mm ( measure ultrasonographically ) plaque volume carotid bulb great equal 4 μl less equal 500 μl Body mass index &gt; 30 Any type know secondary hypertension Electrocardiographic evidence 2nd 3rd degree atrioventricular block , atrial fibrillation , cardiac arrhythmia require therapy bradycardia rest ( &lt; 50/min ) Obstructive pulmonary disease Claudicatio intermittens History clinical evidence significant gastrointestinal , respiratory , hematological , metabolic , immunological underlying disease opinion investigator would interfere patient 's participation trial Hypersensitivity contraindication ARBs , BetaBlockers , HCTZ cross allergy Pretreatment ARBs ACE inhibitor within 6 month prior screen Treatment disallow medication Pregnant breastfeeding female females childbearing potential without adequate contraception History alcohol and/or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2007</verification_date>
</DOC>